Inostics, a molecular diagnostics firm providing blood-based mutation testing, has received the Clinical Laboratory Improvement Amendments (CLIA) license for its clinical laboratory in Baltimore. The receipt of the license would mark a ...
Tags: Clia Certification, Medicine
Sequenta has introduced a sequencing-based test for minimal residual disease (MRD) for leukemia and lymphoma. The ClonoSIGHT test utilizes the company's proprietary LymphoSIGHT technology, which works by sequencing DNA signatures that are ...
Tags: Sequenta, sequencing-based test, minimal residual disease
SWOG (formerly the Southwest Oncology Group) has chosen Sequenta's LymphoSIGHT platform for the measurement of minimal residual disease (MRD) in 180-patient mantle cell lymphoma clinical trial. The patients in the SWOG S1106 mantle cell ...
Tags: SWOG, Sequenta's LymphoSIGHT platform, minimal residual disease, MRD